Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Spr 741
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Northern Antibiotics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Prokaryotics Announces Licensing Agreement with Northern Antibiotics
Details : Prokaryotics gains worldwide rights to develop, manufacture and commercialize the Gram-negative antibiotic potentiator NAB741 (previously known as SPR741).
Product Name : NAB741
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 26, 2025
Lead Product(s) : Spr 741
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Northern Antibiotics
Deal Size : Undisclosed
Deal Type : Licensing Agreement